CSL Behring recently announced that the US Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. CSL Behring is headquartered in Melbourne, Australia, and King of Prussia, PA, in the US.
Indications: Hizentra is indicated for the treatment of:
- Primary immunodeficiency (PI) in adults and pediatric patients aged ≥2 years.
- Maintenance therapy in adults with CIDP.
Dosage/administration: Hizentra is for subcutaneous infusion only. Before switching to Hizentra, physicians should obtain the patient’s serum IgG trough level to guide subsequent dose adjustments. Additional information about dosing can be found here: http://labeling.cslbehring.com/PI/US/Hizentra/EN/Hizentra-Prescribing-Information.pdf.
Adverse reactions: The most common adverse reactions observed in ≥5% of study subjects were local infusion site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis.
FDA approves Hizentra (immune globulin subcutaneous [human] 20% liquid) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). [news release]. Melbourne, Australia, and King of Prussia, PA: CSL Behring. March 16, 2018. https://www.prnewswire.com/news-releases/fda-approves-hizentra-immune-globulin-subcutaneous-human-20-liquid-for-the-treatment-of-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-300615161.html. Accessed March 27, 2018.
This Week's Must Reads
Social Cognitive Theory and Physical Activity in MS, Int J MS Care; 2018 May/June; Uszynski, Casey, et al
Wheeled Mobility Device Intervention Found Feasible, Int J MS Care; 2018 May/June; Rice, Isaacs, et al
Somatic Symptoms of Depression/Anxiety in MS, Int J MS Care; 2018 May/June; Jones, Salem, et al
Turning: Important Marker of Gait and Balance in MS, PLoS One; ePub 2018 Jun 7; Adusumilli, Lancia, et al
Autonomic Dysfunction Compared in Patients with MS, Clin Neurophysiol; 2018 Aug; Adamec, Crnošija, et al
Must Reads in FDA Actions
FDA Approves Medtronic’s DBS Therapy for Epilepsy, Medtronic news release; 2018 May 1
FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16
FDA Approves Apadaz for Acute Pain Relief, KemPharm, Inc. news release; 2018 Feb 23
FDA Expands Treatment Time for Clot Retrieval Device, FDA news release; 2018 Feb 15